These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25104067)

  • 1. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.
    Wuthrick EJ; Curran WJ; Camphausen K; Lin A; Glass J; Evans J; Andrews DW; Axelrod R; Shi W; Werner-Wasik M; Haacke EM; Hillman GG; Dicker AP
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):369-75. PubMed ID: 25104067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
    Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.
    Reynaud T; Bertaut A; Farah W; Thibouw D; Crehange G; Truc G; Vulquin N
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806498. PubMed ID: 30343637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
    Wuthrick EJ; Kamrava M; Curran WJ; Werner-Wasik M; Camphausen KA; Hyslop T; Axelrod R; Andrews DW; Glass J; Machtay M; Dicker AP
    Cancer; 2011 Dec; 117(24):5548-59. PubMed ID: 21647871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas.
    Shi W; Palmer JD; Werner-Wasik M; Andrews DW; Evans JJ; Glass J; Kim L; Bar-Ad V; Judy K; Farrell C; Simone N; Liu H; Dicker AP; Lawrence YR
    J Neurooncol; 2016 May; 127(3):535-9. PubMed ID: 26821711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.
    Wetmore C; Daryani VM; Billups CA; Boyett JM; Leary S; Tanos R; Goldsmith KC; Stewart CF; Blaney SM; Gajjar A
    Cancer Med; 2016 Jul; 5(7):1416-24. PubMed ID: 27109549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
    Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma.
    Reardon DA; Vredenburgh JJ; Coan A; Desjardins A; Peters KB; Gururangan S; Sathornsumetee S; Rich JN; Herndon JE; Friedman HS
    J Neurooncol; 2011 Dec; 105(3):621-7. PubMed ID: 21744079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial.
    Cabrera AR; Cuneo KC; Desjardins A; Sampson JH; McSherry F; Herndon JE; Peters KB; Allen K; Hoang JK; Chang Z; Craciunescu O; Vredenburgh JJ; Friedman HS; Kirkpatrick JP
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):873-9. PubMed ID: 23725997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma.
    Hudes RS; Corn BW; Werner-Wasik M; Andrews D; Rosenstock J; Thoron L; Downes B; Curran WJ
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):293-8. PubMed ID: 10030252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irradiation and bevacizumab in high-grade glioma retreatment settings.
    Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
    Den RB; Kamrava M; Sheng Z; Werner-Wasik M; Dougherty E; Marinucchi M; Lawrence YR; Hegarty S; Hyslop T; Andrews DW; Glass J; Friedman DP; Green MR; Camphausen K; Dicker AP
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):321-8. PubMed ID: 22687197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
    Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
    Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
    J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
    Guan Y; Xiong J; Pan M; Shi W; Li J; Zhu H; Gong X; Li C; Mei G; Liu X; Pan L; Dai J; Wang Y; Wang E; Wang X
    BMC Cancer; 2021 Feb; 21(1):123. PubMed ID: 33546642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma.
    Saad E; Abdelwahed M; Moussa R; Abdulla M
    Asian Pac J Cancer Prev; 2024 Jul; 25(7):2499-2507. PubMed ID: 39068585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.
    Gutin PH; Iwamoto FM; Beal K; Mohile NA; Karimi S; Hou BL; Lymberis S; Yamada Y; Chang J; Abrey LE
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):156-63. PubMed ID: 19167838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy.
    Baumann KH; du Bois A; Meier W; Rau J; Wimberger P; Sehouli J; Kurzeder C; Hilpert F; Hasenburg A; Canzler U; Hanker LC; Hillemanns P; Richter B; Wollschlaeger K; Dewitz T; Bauerschlag D; Wagner U
    Ann Oncol; 2012 Sep; 23(9):2265-2271. PubMed ID: 22377563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenic blockade and radiotherapy in hepatocellular carcinoma.
    Chi KH; Liao CS; Chang CC; Ko HL; Tsang YW; Yang KC; Mehta MP
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):188-93. PubMed ID: 20133077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.